Harrow Health Inc owns a portfolio of healthcare and ophthalmology pharmaceutical business, including ImprimisRx, an ophthalmology outsourcing facility and pharmaceutical compounding business. The Company holds interest in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The Company also owns royalty rights in four clinical stage drug candidates, which is being developed by Surface Ophthalmics and Melt Pharmaceuticals.